TARGETED METABOLIC CANCER THERAPY CASE REPORT: Borderline High-Risk Prostate Cancer Shows Rapid PSA Reduction (–46%), Near-Complete Inflammation Resolution (–99%), and Hormonal Rebalancing Within 1 Month
Patient profile Age: 65 yearsSex: Male Clinical History Long-standing chronic prostatitis Prior 12-core biopsy (2024) Persistent PSA elevation Diagnosis (2025) Cancer type: Prostate cancer Histology: Acinar...



